REG - BkofA Merrill Lynch Horizon Therapeutics - 20230721_HORIZON THERAPEUTICS PLC_38.5 (b)_BOFAS
24/07/2023 12:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230724:nRSX9741Ga&default-theme=true
RNS Number : 9741G Bank of America Merrill Lynch 24 July 2023
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader BofA Securities, Inc.
Company dealt in HORIZON THERAPEUTICS PLC
Class of relevant security to which the Common - IE00BQPVQZ61
dealings being disclosed relate(Note 1)
Date of dealing 21/07/2023
BofA Securities, Inc.
Company dealt in
HORIZON THERAPEUTICS PLC
Class of relevant security to which the
dealings being disclosed relate(Note 1)
Common - IE00BQPVQZ61
Date of dealing
21/07/2023
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant
security
dealt in (Note 2)
Class of relevant security: Common IE00BQPVQZ61
Long Short
Number % Number %
(1) Relevant securities 370,426 0.162% 862,691 0.377 %
(2) Derivatives (other than options): 1,251,463 0.547% 516,424 0.226%
(3) Options and agreements to purchase/sell: 0 0% 60,000 0.026%
Total 1,621,889 0.709% 1,439,115 0.629%
370,426
0.162%
862,691
0.377 %
(2) Derivatives (other than options):
1,251,463
0.547%
516,424
0.226%
(3) Options and agreements to purchase/sell:
0
0%
60,000
0.026%
Total
1,621,889
0.709%
1,439,115
0.629%
(b) Interests and short positions in relevant securities of the company, other
than the
class dealt in (Note 2)
Class of relevant security:
Long Short
Number % Number %
(1) Relevant securities 0 0% 0 0%
(2) Derivatives (other than options): 0 0% 0 0%
(3) Options and agreements to purchase/sell: 0 0% 0 0%
Total 0 0% 0 0%
0
0%
0
0%
(2) Derivatives (other than options):
0
0%
0
0%
(3) Options and agreements to purchase/sell:
0
0%
0
0%
Total
0
0%
0
0%
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 4)
Purchase 25,731 101.18 USD
Purchase 80 101.43 USD
Purchase 200 101.46 USD
Purchase 200 101.48 USD
Purchase 100 101.49 USD
Purchase 700 101.5 USD
Purchase 664 101.51 USD
Purchase 30,000 100.9 USD
Purchase 562,000 101.337 USD
Purchase/sale Number of relevant securities Price per unit (Note 4)
Sale 100 100.725 USD
Sale 1,955 100.73 USD
Sale 1,332 100.74 USD
Sale 2,310 100.75 USD
Sale 2,659 100.76 USD
Sale 400 100.765 USD
Sale 1,980 100.77 USD
Sale 4,846 100.78 USD
Sale 2,684 100.79 USD
Sale 1,513 100.8 USD
Sale 100 100.805 USD
Sale 1,107 100.81 USD
Sale 6,600 100.82 USD
Sale 200 100.825 USD
Sale 6,178 100.83 USD
Sale 400 100.835 USD
Sale 6,503 100.84 USD
Sale 3,618 100.85 USD
Sale 100 100.855 USD
Sale 3,082 100.86 USD
Sale 200 100.865 USD
Sale 1,011 100.87 USD
Sale 3,637 100.88 USD
Sale 100 100.885 USD
Sale 600 100.89 USD
Sale 100 100.895 USD
Sale 49,069 100.9 USD
Sale 100 100.905 USD
Sale 7,766 100.91 USD
Sale 1,940 100.92 USD
Sale 803 100.93 USD
Sale 4,838 100.94 USD
Sale 1,904 100.95 USD
Sale 4,031 100.96 USD
Sale 479 100.965 USD
Sale 2,045 100.97 USD
Sale 200 100.975 USD
Sale 3,733 100.98 USD
Sale 1,100 100.99 USD
Sale 1,900 100.995 USD
Sale 10,258 101 USD
Sale 3,400 101.005 USD
Sale 33,214 101.01 USD
Sale 1,302 101.015 USD
Sale 10,087 101.02 USD
Sale 100 101.025 USD
Sale 2,711 101.03 USD
Sale 3,654 101.04 USD
Sale 3,018 101.05 USD
Sale 7,304 101.06 USD
Sale 410 101.065 USD
Sale 3,742 101.07 USD
Sale 4,500 101.075 USD
Sale 6,799 101.08 USD
Sale 101 101.09 USD
Sale 3,128 101.1 USD
Sale 200 101.105 USD
Sale 3,339 101.11 USD
Sale 1,320 101.12 USD
Sale 100 101.125 USD
Sale 4,986 101.13 USD
Sale 1,079 101.14 USD
Sale 1,717 101.15 USD
Sale 1,700 101.155 USD
Sale 100 101.16 USD
Sale 390 101.17 USD
Sale 100 101.175 USD
Sale 313,334 101.18 USD
Sale 5,230 101.185 USD
Sale 100 101.188 USD
Sale 10,246 101.19 USD
Sale 300 101.195 USD
Sale 5,332 101.2 USD
Sale 600 101.205 USD
Sale 12,365 101.21 USD
Sale 2,600 101.215 USD
Sale 100 101.218 USD
Sale 8,746 101.22 USD
Sale 2,100 101.225 USD
Sale 4,358 101.23 USD
Sale 800 101.235 USD
Sale 2,129 101.24 USD
Sale 5,700 101.25 USD
Sale 700 101.255 USD
Sale 4,135 101.26 USD
Sale 3,333 101.27 USD
Sale 900 101.275 USD
Sale 4,227 101.28 USD
Sale 800 101.285 USD
Sale 4,582 101.29 USD
Sale 200 101.295 USD
Sale 1,188 101.3 USD
Sale 2,713 101.31 USD
Sale 900 101.315 USD
Sale 1,706 101.32 USD
Sale 4,141 101.33 USD
Sale 1,100 101.34 USD
Sale 4,425 101.35 USD
Sale 2,004 101.36 USD
Sale 5,948 101.37 USD
Sale 200 101.375 USD
Sale 5,264 101.38 USD
Sale 1,100 101.39 USD
Sale 853 101.4 USD
Sale 100 101.405 USD
Sale 1,778 101.41 USD
Sale 105 101.42 USD
Sale 1,354 101.43 USD
Sale 100 101.44 USD
Sale 5,051 101.5 USD
Sale 100 101.505 USD
Sale 3,202 101.51 USD
Sale 5 101.516 USD
Sale 24,883 101.52 USD
Sale 900 101.525 USD
Sale 5 101.526 USD
Sale 17,130 101.53 USD
Sale 1,600 101.535 USD
Sale 100 101.537 USD
Sale 100 101.538 USD
Sale 24,760 101.54 USD
Sale 17 101.544 USD
Sale 700 101.545 USD
Sale 15,037 101.55 USD
Sale 2,708 101.555 USD
Sale 9 101.556 USD
Sale 100 101.557 USD
Sale 10,608 101.56 USD
Sale 500 101.565 USD
Sale 8,716 101.57 USD
Sale 1,700 101.575 USD
Sale 200 101.577 USD
Sale 7,019 101.58 USD
Sale 900 101.585 USD
Sale 6,372 101.59 USD
Sale 200 101.595 USD
Sale 9,616 101.6 USD
Sale 200 101.605 USD
Sale 7,203 101.61 USD
Sale 348 101.615 USD
Sale 200 101.619 USD
Sale 2 101.62 USD
Sale 1,000 101.63 USD
Sale 200 101.635 USD
Sale 191 101.64 USD
Sale 4,208 101.65 USD
Sale 100 101.655 USD
Sale 1,602 101.66 USD
Sale 3,628 101.67 USD
Sale 100 101.675 USD
Sale 1,214 101.68 USD
Sale 2,814 101.69 USD
Sale 200 101.695 USD
Sale 3,808 101.7 USD
Sale 600 101.705 USD
Sale 1,854 101.71 USD
Sale 136 101.715 USD
Sale 1,301 101.72 USD
Sale 100 101.725 USD
Sale 49 101.726 USD
Sale 2,700 101.73 USD
Sale 1,300 101.74 USD
Sale 6,685 101.75 USD
Sale 100 101.751 USD
Sale 100 101.755 USD
Sale 51 101.759 USD
Sale 2,842 101.76 USD
Sale 400 101.765 USD
Sale 66 101.768 USD
Sale 3,148 101.77 USD
Sale 500 101.775 USD
Sale 40 101.777 USD
Sale 4,760 101.78 USD
Sale 200 101.785 USD
Sale 3,892 101.79 USD
Sale 49 101.791 USD
Sale 37 101.795 USD
Sale 100 101.798 USD
Sale 3,400 101.8 USD
Sale 500 101.805 USD
Sale 1,912 101.81 USD
Sale 100 101.815 USD
Sale 2,236 101.82 USD
Sale 72 101.826 USD
Sale 1,200 101.83 USD
Sale 200 101.84 USD
Sale 100 101.86 USD
Sale 700 101.87 USD
Sale 900 101.88 USD
Sale 900 101.89 USD
Sale 3,999 101.9 USD
Sale 700 101.91 USD
Sale 970 101.92 USD
Sale 30 101.925 USD
Sale 1,099 101.93 USD
Sale 1,060 101.94 USD
Sale 2,168 101.95 USD
Sale 400 101.955 USD
Sale 2,767 101.96 USD
Sale 200 101.965 USD
Sale 3,378 101.97 USD
Sale 2,343 101.98 USD
Sale 3,499 101.99 USD
Sale 200 101.991 USD
Sale 698 102 USD
Sale 100 102.004 USD
Sale 490 102.01 USD
Sale 1,020 102.02 USD
Sale 2,204 102.03 USD
Sale 1,989 102.04 USD
Sale 100 102.045 USD
Sale 32 102.046 USD
Sale 2,342 102.05 USD
Sale 1,256 102.06 USD
Sale 3,328 102.07 USD
Sale 27,675 101.18 USD
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD
(Note 5) (Note 6)
(Note 4)
Swaps Opening a Long Position 15,776 100.85 USD
Swaps Increasing a Long Position 300,839 101.18 USD
Swaps Opening a Long Position 295,371 101.286 USD
Swaps Reducing a Short Position 1 101.77 USD
Swaps Closing a Long Position 161,544 101.337 USD
Swaps Opening a Short Position 133,827 101.337 USD
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc Expiry date Option money paid/ received per unit (Note 4)
N/A N/A N/A N/A N/A N/A N/A
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option
unit (Note 4)
N/A N/A N/A
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature or transaction Details Price per unit
(Note 7)
(if applicable) (Note 4)
Borrow Borrow of 4 shares N/A
Loan Loan of 4 shares N/A
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights
or future acquisition or disposal of any relevant securities to which any
derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 38.5(b) attached? (Note 8) No
Date of disclosure 24/07/2023
Contact name Frank Lui
Telephone number +44207 996 6418
Name of offeree/offeror with which connected AMGEN INC
Nature of connection (Note 9) Advisor to - AMGEN INC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ITPZZGZNGDGGFZMRecent news on Amgen
See all newsREG - BkofA Merrill Lynch Horizon Therapeutics - 20231005_HORIZON THERAPEUTICS PLC_38.5 (a)_IE_MLI
AnnouncementREG - BkofA Merrill Lynch Horizon Therapeutics - 20231005_HORIZON THERAPEUTICS PLC_38.5 (b)_IE_BANA
AnnouncementREG - BkofA Merrill Lynch Horizon Therapeutics - 20231005_HORIZON THERAPEUTICS PLC_38.5(b)_IE_BOFAS
AnnouncementREG - Irish Takeover Panel - Disclosure Table
AnnouncementREG - D E Shaw & Co LP Horizon Therapeutics Amgen Inc. - Form 8.3 - Horizon Therapeutics plc
Announcement